Letter to the EditorAtorvastatin therapy reduces serum uric acid levels: A meta-analysis of randomized controlled trials
References (18)
- et al.
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?
Metabolism
(2006) - et al.
Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease
Am J Cardiol
(2002) - et al.
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study
Am J Kidney Dis
(2004) - et al.
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
Am Heart J
(2004) - et al.
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia
Atherosclerosis
(2001) - et al.
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients
Atherosclerosis
(2000) - et al.
Lovastatin retards the progression of established glomerular disease in obese Zucker rats
Am J Kidney Dis
(1993) - et al.
A role for uric acid in the progression of renal disease
J Am Soc Nephrol
(2002) - et al.
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey
JAMA
(2000)
Cited by (17)
Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications
2022, Mayo Clinic ProceedingsCitation Excerpt :A systematic review and meta-analysis by Derosa et al23 incorporated 9 RCTs and found significant reductions in sU levels with use of atorvastatin (MD (mean difference) –39.62 μmol/L; 95% CI, –60.78 to –18.46 μmol/L; P<.001) and simvastatin (MD –5.95 μmol/L; 95% CI, –10.62 to –1.28 μmol/L; P=.013) but not with use of pravastatin, rosuvastatin, or lovastatin. Thus, across multiple studies, a consistent signal for limited urate lowering is seen with atorvastatin, with mixed data on a possible benefit of rosuvastatin and simvastatin and no beneficial effect with other statins.24 On the other hand, colchicine is used by many patients with gout, and because of interactions at the CYP3A4 hepatic enzyme, atorvastatin but not some other statins must be used with caution when administered with colchicine.63
Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus
2018, Metabolism: Clinical and ExperimentalCitation Excerpt :This would, in turn, increase the renal blood flow and the glomerular filtration rate, which ultimately influences uric acid levels [99]. Further, atorvastatin, similar to other statins, contributes to improve insulin resistance and this may lead to a decrease in urate synthesis [100]. This narrative review resulted from a non-systematic revision of the literature and summarized the epidemiologic evidences and the pathophysiologic mechanisms responsible for UAN under insulin resistance conditions.
Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis
2016, International Journal of CardiologyCitation Excerpt :Recent studies indicate that statins can influence arterial wall stiffness in various ways. The lipid-independent effects of statins have been hypothesized to be due to their pleiotropic effects on vessel wall [6,7] as well as anti-inflammatory [8,9], antioxidant [10,11], anti-thrombotic [12] and hypouricemic [13]. Statins can stabilize atherosclerotic plaques which might have an effect on arterial stiffness because of a rapid reduction of lipid vascular contents.
A low-density lipoprotein-dependent effect of atorvastatin upon the systolic blood pressure reduction: Meta-regression analyses of randomized trials
2013, International Journal of CardiologyLow-density lipoprotein-dependent and independent effects of statins on prevention of major coronary events: Meta-regression of randomized placebo-controlled trials
2013, International Journal of CardiologyOld Drugs for New Indications in Cardiovascular Medicine
2018, Cardiovascular Drugs and Therapy